We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 60.50 | 60.00 | 61.00 | 60.50 | 60.50 | 60.50 | 14,770 | 07:44:37 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -2.77 | 8.07M |
Date | Subject | Author | Discuss |
---|---|---|---|
27/9/2019 23:46 | Do you think they will sell Texrad eventually? | hope67 | |
27/9/2019 21:52 | FDBK's rns in conjunction with IQAI'S implies that the BOD are waiting confirmation/clarifi | 2seabass | |
27/9/2019 21:45 | StoneChecker is medical imaging software used to measure key kidney stone parameters to generate a set of textual metrics. It uses an application (TexRAD, licensed by Feedback Medical Ltd) that analyses the texture in an existing radiological scan. The aim is to help clinicians assess a stone's heterogeneity and any characteristics not visible to the naked eye. It creates a visual 'map' of a kidney stone. The technology is designed to be used with conventional CT scans to help clinical decision making about diagnosing and treating people with kidney stones. It imports imaging data and calculates metrics based on individual pixel data points within a given region of interest. These metrics assess stone heterogeneity, including texture irregularity, not provided by conventional CT scans. The technology can also use filters to extract and enhance existing CT images to help assess stone composition. This can potentially be used to predict treatment failure on pre-treatment CT, and to identify and select patients who are most likely to benefit from the treatment. StoneChecker software runs on existing Windows-based machines or workstations, and can be integrated with a hospital picture archiving and communication system to import files containing CT images. Innovations StoneChecker uses an algorithm aimed at measuring the size and volume of kidney stones. It can also assess stone heterogeneity using filtration-histogram the details seen with conventional CT. Currently, there is no standardised method of measuring the physical and texture parameters that enable clinicians to predict treatment outcomes. | formula1187 | |
27/9/2019 20:57 | Definitely tongue in cheek Duc. I have to smiley face my whimsy now for fear of offending others. However, I do agree with you, the board seem to have a knack of depressing the share price on a regular basis. | lr2 | |
27/9/2019 20:43 | #FDBK #AQAI Feedback surges as TexRAD licensee StoneChecker receives green light from FDA | newtothisgame3 | |
27/9/2019 19:32 | Duc, they must have seen the share price rising and knowing they couldn't buy in before the year end results are announced they decided to pour iced water on the share price heat. :) | lr2 | |
27/9/2019 19:24 | Ged, well found. There was discussion here some months back with regard to Texrad/stonechecker. From memory I think there was a post which contained your findings also that under certain circumstances that fdbk could withdraw their permission for stonechecker to use Texrad. It is obvious from the RNS that the Co' have lost any documentation or don't know where to find it. Let's hope your post is of help. Personally I have no idea why they issued this statement today. It was not necessary and makes the Co' look foolish. Edit, the share price wasn't exactly flying either was it!? | ducatiman | |
27/9/2019 16:42 | BOD obviously spent most of the day going through filing cabinets for documents. I would imagine F.Freddy took them with him, lol. Another fine mess Olly! | ducatiman | |
27/9/2019 16:17 | BOTAK - your not selling out? Don't do it! | petekand | |
27/9/2019 16:13 | wow 22m shares traded today, I think that's about 4% of the company. and obviously even more of the free float | davydoo | |
27/9/2019 16:11 | No all I can find is this 'Bleepa @BleepaMe · Jul 29 Replying to @haze2947 Absolutely! #Bleepa is aimed initially at healthcare applications but there are many potential industries that would benefit from secure, high res messaging...watch this space ' | hazl | |
27/9/2019 16:03 | Pete some good posts the RNS could perhaps have been more succinct. | hazl | |
27/9/2019 16:02 | I certainly remember seeing or hearing the word 'transformational' somewhere. I think it was when I replied to one of Bleepa's tweets or it could have been in the video. More related to other uses of Bleepa perhaps from memory. | hazl | |
27/9/2019 16:02 | i,m Throwing in the Towel,Just cant take anymore of this insane drivel , Good Luck all | botak54 | |
27/9/2019 15:57 | so technology is our's lol | formula1187 | |
27/9/2019 15:40 | I think it is a reasonable RNS, after all Stonechecker has been available to Europe since 2017 when IQAI was known as Flying brands and it has done little for either companies revenue. | bandflex | |
27/9/2019 15:33 | Well done tops Missed your 2 x 100k buys earlier seconds apart 2 x 150k sells seconds apart at 1.255p You always squeeze out a profit | dave4545 | |
27/9/2019 15:32 | LR2 - no problem my friend. | petekand |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions